Report details a rare case of plasmacytoid carcinoma in the prostatic urethra, highlighting treatment challenges.
Plasmacytoid carcinoma is a rare and aggressive histological subtype of urothelial carcinoma, accounting for between 1% and 3% of urothelial carcinomas. The diagnostic confirmation relies on morphological and immunohistochemical analysis. We report the case of a 65-year-old male patient diagnosed with plasmacytoid urothelial carcinoma of the prostatic urethra (T4, N0, M0), with histological confirmation based on a biopsy obtained by transurethral resection. Immunohistochemical studies revealed positive epithelial markers and negative lymphoid markers. The patient underwent two cycles of systemic cisplatin-based chemotherapy. Surgery will be considered after further assessment. The therapeutic approach remains debated due to the heterogeneity of this histological subtype and its rarity. Radical cystectomy is the standard treatment for invasive muscle tumors without metastasis. Although cisplatin-based chemotherapy has been reported to be effective, local and metastatic recurrences are frequent. However, larger studies are needed to draw definitive conclusions and achieve consensus.
No takes yet. Share an insight, caveat, or question.
Khouz et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: